About

NeoMedigen is a Bio-tech Creating Dual Purpose Super Drugs that Treat as well as Prevent Multiple Diseases of Aging, Cancer, Viral Infections, Inflammation, Alzheimer's & Type 2 Diabetes

The company is currently focusing its operational resources on clinical research and its drug development program at Harvard Beth Israel Hospital, Penn University and UMASS Medical Center. The clinical's will ascertain the highest and best use in the areas of oncology, dermatology and nutrigenomics of NeoMedigen’s synergized molecule, RezGen5.

NeoMedigen and its research partners are focused on RezGen5 and how it can activate sirtuins and DNA repair capacity in vivo, in order to take advantage of the recent advances demonstrating both in dividing cells and, also non-dividing repair capacities involved in modulating DNA repair compositions.

NeoMedigen, Preclinical studies performed at Brunswick Laboratories’ with Rezgen5, has demonstrated potential importance in multiple disease areas, including Type 2 diabetes and related complications, cardiovascular, inflammatory and neurodegenerative diseases.

NeoMedigen researchers will be working to translate this research into a potential new class of pharmaceuticals to treat diseases of ageing, offering the ability for people to live longer, healthier lives.